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Abstract 
Considerable progress has been made in the prevention, diagnosis and 
management of pediatric patients with invasive fungal disease (IFD). The reported 
decreasing trend in the incidence of invasive candidiasis (IC) over the last 15 years in 
both neonates and children has been encouraging. Nevertheless, a growing population 
of immunocompromised hosts has increased the number of children at risk for IFD, 
which continues to be associated with significant morbidity and mortality as well as 
increased financial burden to the health care system. Therefore, it is important to 
understand the contemporary epidemiology of IFD. Incidence rates of IFD in children 
are impacted by geographical, population and time variability. There is an ongoing 
effort to constantly update the incidence and the species distribution causing IFD 
among different pediatric populations as a means to target preventative, diagnostic 
and therapeutic resources to the most appropriate subset of patients. Among children 
vulnerable to IFD, patients with hematologic malignancies, primary or secondary 
immunodeficiencies, patients undergoing solid organ or hematopoietic stem cell 
transplantation, and premature neonates are the major subsets of pediatric patients at 
risk of developing IFD. This review focuses on fungal disease epidemiology with 
specific emphasis on the two most common pediatric IFD, IC and invasive 
aspergillosis (IA).  
 
Introduction 
Invasive fungal disease (IFD) is a major cause of morbidity and mortality 
among immunocompromised and hospitalized pediatric patients [1,2]. There has been 
a significant increase in pediatric patients at risk of IFD, primarily due to increasing 
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utilization of immunosuppressive medications across many medical specialties.  
Simultaneously, there have been advances in the management of IFD via novel fungal 
diagnostic tests and evidenced-based utilization of antifungal agents for prophylaxis 
and treatment. Collectively, these factors have altered the epidemiology and outcomes 
of IFD over the last 15 years [3,4].  
The spectrum of pediatric patients vulnerable to IFD is wide and includes 
children receiving chemotherapy for malignancies, recipients of hematopoietic stem 
cell (HCT) and solid organ (SOT) transplants, children with primary 
immunodeficiencies, children receiving immune modulating therapies for 
autoimmune conditions, and those with acquired immunodeficiency.  Beyond these 
patient groups, neonates and children hospitalized in the intensive care unit, among 
other groups, are also at risk for IFD [5-10]. The wide range of pediatric populations 
at risk for IFD makes it challenging to maintain contemporary estimates of 
epidemiology to guide clinical decision-making.  
Despite these challenges, a recent increased focus on IFD in the pediatric 
literature has provided clinicians with reasonable estimates of IFD in at risk 
populations.  Candida spp. remain the leading cause of IFD among pediatric patients 
and are the fourth most common pathogen detected in hospital-acquired pediatric 
blood stream infections (BSIs) in the United States and Europe [2,11-13]. Aspergillus 
species and organisms from the Mucorales family remain the leading cause of 
invasive mold disease (IMD). [14,15].  
 This review summarizes the contemporary literature on the epidemiology of 
IFD in pediatric patients with malignancies, transplant recipients, children with 
primary immunodeficiency, and those managed in the pediatric (PICU) and neonatal 
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intensive care units (NICU).  As previously noted, there are other sub-populations of 
children at risk for IFD, yet as data on IFD epidemiology in these populations are 
limited they are not included in this discussion.  Future investigations are necessary to 
better define the risk of IFD in these other populations.  
  
Overall IFD Epidemiology 
Both candidemia and IA are associated with significant increases in hospital 
length of stay and an overall in-hospital mortality of 15.8% for pediatric candidemia 
and 18% for children with IA [12,13]. In an attempt to estimate the attributable 
financial burden of IFD to the health care system, a cost analysis study revealed that 
the increase of total hospital charges to treat IC for non-neonatal pediatric patients are 
$65,058 - $119,474 per episode [12]. Similarly, for children with invasive 
aspergillosis (IA) the median healthcare cost reached $49,309 per episode [13].  
Globally, there are a number of pediatric multicenter studies that have 
documented the incidence of IC and IA (Table 1) [16-21], as well as the distribution 
of fungal pathogens in children (Tables 2 and 3). The largest international 
collaborative studies assessing the incidence of IC and IA in children were conducted 
by the International Pediatric Fungal Network (IPFN; www.ipfn.org) [14, 22]. A 
predominance of non-albicans Candida spp. in both pediatric (56%) and neonatal 
(52%) patients were found by the IPFN [22], with similar distribution of C. albicans 
and C. parapsilosis as reported in other pediatric studies in Latin America, USA and 
Europe [23-25]. In particular, a South American surveillance study found C. albicans 
(pediatric 43.8% and neonatal 35.7%) and C. parapsilosis (pediatric 27.0% and 
neonatal 26.3%) prevailed [23]. A higher incidence of C. parapsilosis infection both 
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in neonates (42%) and in pediatric patients (38%) was noticed in an Australian 
prospective candidemia study revealing a possible difference of geographic Candida 
niches [26]. A European multi-center study to define Candida spp. distribution among 
pediatric patients (EURO-CANDY study) is currently ongoing and led by the 
European Pediatric Mycology Network (EPMyN) [27]. 
Epidemiology of invasive mold disease (IMDs) in children revealed that A. 
fumigatus and A. flavus are the predominant mold isolated  [14]. Beyond Aspergillus 
spp., pathogens from the Mucorales family were the causative agent in 13%, with 
Rhizopus and Mucor  prevailing [14]. A single centre study reported comparable 
fungal epidemiology among pediatric patients, with Aspergillus spp. accounting for 
40% of the IMDs, followed by Mucorales (20%) and Fusarium spp. (11%) [28]. Two 
large international registries (Zygomyco.net and FungiScope™) characterized 
paediatric-specific data surrounding the underlying fungal epidemiology in 
mucormycosis., Rhizopus spp. predominated (39.7 %), followed by Lichtheimia spp. 
(17.5 %) and Mucor spp. (12.7 %) [29]. 
 
Invasive fungal disease in pediatric patients with malignancies and 
hematopoietic stem cell transplantation (HCT) recipients 
It is challenging to define the incidence of IFD in children with cancer, as the 
incidence will vary by chemotherapy regimen and supportive care practices [30, 31]. 
Furthermore, the criteria for defining and diagnosing IFD have varied over time and 
application of these definitions varies by study [30-33]. Inconsistencies in IFD 
diagnostic criteria might impact the true estimate of IFD rates among these patients 
and therefore make the comparison among different chemotherapy protocol groups 
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difficult [31].  Despite these challenges, early diagnosis and prompt initiation of 
effective antifungal therapy remains as one of the important actions necessary for 
improving IFD outcomes in pediatric patients with malignancies [4, 30,32,33].  
Epidemiology. The incidence of IFD in children receiving chemotherapy for 
cancer and those undergoing HCT remains high and is associated with increased 
morbidity and mortality [30]. Two studies nicely illustrate the changing landscape of 
IFD within similar cohorts of children with AML [34, 35]. The rate of IFD reached 
almost 5% using the AML-BFM 93 chemotherapy protocol, while in the same 
population the IFD incidence decreased to 3% with the more intensified BFM AML 
2004 protocol [34, 35]. The lower number of IFD in the BFM AML 2004 study may 
be partially attributed to the broader administration of antifungal prophylaxis (in 
>70% of the chemotherapy cycles) with a preference for drugs with anti-mold activity 
[35]. As a comparator, in a French study including 387 children with AML receiving 
the ELAM 02 chemotherapy protocol from 2005-2011, the incidence rate of IFD was 
6.7% [36]. In the US, a higher incidence of IFD in children with AML enrolled on 
CCG 2961 protocol by the Children's Cancer Group (CCG) was reported [37]. These 
differences in IFD incidence have been partially explained by international variations 
in infection supportive care practices among the BFM and CCG groups for pediatric 
patients with AML [31]. In particular, BFM centres more frequently provided 
antifungal prophylaxis compared to Children’s Oncology Group centers, including 
utilization of antifungal agents with anti-mold activity (63.8% vs 14.4%) [31].  
The inconsistent utilization of antifungal prophylaxis and choice of 
prophylactic agent also has an impact on reported IFD rates among pediatric patients 
with malignancies.  Without antifungal prophylaxis, mixed population of  pediatric 
patients with malignancies reported rates of IFD between 2.9 - 7.8% [38,39]. In 
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specific pediatric cancer populations, an IFD rate of 6.1% was observed in patients 
with promyelocytic AML in a retrospective Canadian study without antifungal 
prophylaxis and 8.4 % (or IFD incidence of 0.84/1000 person-days) in non-
lymphoblastic leukemia patients in an Italian study, respectively [40,41]. In patients 
receiving antifungal prophylaxis, Watanabe et al. reported an IFD rate of  3.8% 
(6/158 cases) in a mixed population of patients with leukemia and lymphoma 
receiving oral amphotericin B or intravenous fluconazole [42]. Koyabashi et al. in a 
mixed population of pediatric patients with hematological malignancies or children 
undergoing HCT receiving antifungal prophylaxis reported an IFD rate of 6.9% 
(23/334 cases) [43]. By comparison, Kaya et al. reported an IFD rate of 13.6% 
(proven 7.2%) among children with leukemia receiving fluconazole prophylaxis [44].  
Candida and Aspergillus spp. are the predominant pathogens causing IFD in 
children with malignancies, while an increasing shift towards other non-Aspergillus 
molds (Fusarium, Scedosporium and Mucorales) has recently been observed [3,4, 30, 
45]. During a ten year period, the average annual incidence of candidemia among 
pediatric oncology/HCT patients was 1.25 cases/1000 hospital discharges [45].  
Although C. albicans is the most frequent species isolated, there is also an increasing 
trend for non-albicans Candida spp. in children with cancer, most frequently C. 
parapsilosis and C. tropicalis [22, 30, 45]. A. fumigatus is the most common cause of 
IA in children with hematologic malignancy, followed by A. flavus and A. terreus [14, 
15, 28].  Among non-Aspergillus molds, pathogens from the Mucorales family 
accounted for 13% while all other non-Aspergillus and non-Mucorales molds 
represented 17% of the IFD cases [14].  
Outcomes. The overall case-fatality rate of IFDs ranges between 10% and 
70%, with higher rates observed in specific subpopulations such as the patients with 
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disseminated IFD, CNS involvement, or persistent neutropenia [30,41, 43]. Kobayashi 
et al. reported an IFD case fatality rate of 48.2%, and up to 71.4% in patients with 
lung involvement [43].  For CNS aspergillosis, case-fatality rates before 1990 reached 
80%, while after 1990 mortality rates decreased significantly to 39.5% [46]. For IC, 
overall fatality rates range between 10% and 25%, but can reach close to 50% in 
patients with ICU admission [30]. In a French study of children with AML, the 
overall survival at 24 months for children diagnosed with IFD was 72% [36]. The 
case-fatality rates of IMDs in most studies are between 20% and 50%, increasing to 
approximately 80% in patients with allogeneic HCT [14, 15, 30, 47]. Pana et al. found 
a case fatality rate of almost 40% for mucormycosis in children suffering from 
hematological malignancies and 80% for HCT patients [29].  
 
Invasive fungal disease in pediatric solid organ transplant (SOT) recipients 
Epidemiology. The true burden of IFD as well as the species distribution 
following solid organ transplantation has been evaluated in few studies. A US 
multicenter prospective study (TRANSNET) employing IFD surveillance among 
mainly adult SOT recipients reported a marginal increase of IFD from 2000-2006, 
with the highest rates observed among small bowel, lung and liver transplantation, 
respectively [48]. In an attempt to analyze only the pediatric (SOT) recipient’s cases 
from the TRANSNET database, Knapp K et al., reviewed 49 IFD episodes among 41 
pediatric SOT recipients (3% of all SOT recipients in the TRANSNET cohort) [49]. 
The most common organisms detected were Candida spp. (78%), followed by 
Aspergillus spp. (8%) [49].  
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Organ-specific data of IFD in pediatric SOT recipients are limited [50-54]. A 
study with 98 pediatric liver transplant recipients revealed that 31% presented with 
Candida infections [50]. In a more recently published study, the incidence rate of IC 
in children undergoing liver transplantation is estimated to be 2.5% (10/397) [51]. 
Among the 10 IC cases reported, C. albicans prevailed (50%), followed by C. 
parapsilosis, C. lusitaniae (20% each) and C. guillermondii (10%) [51]. One study 
dedicated to pediatric heart transplant patients showed that Candida infections were 
66% of all IFD, followed by IMD at 16% (82% of them attributed to Aspergillus spp.) 
[52]. Among 83 IFD attributed to yeast infections, C. albicans was the majority 
(55%), followed by C. parapsilosis (13%), C. krusei (4%), C. glabrata and C. 
tropicalis (2% each) [52]. Among 22 IFD attributed to mold infections, 18 were 
caused by Aspergillus spp. (82%) followed by zygomycetes (13.6%) and Exherohilum 
spp. (4.5%) [52]. Results from a multi-center US and European study analyzing 
children undergoing lung transplantation showed that the proven and probable IFD 
rate reached 10.5% with almost equal distribution of Candida and Aspergillus spp. 
[53]. In a single center study with 55 pediatric lung transplant recipients (2002-2007), 
11 patients accounted for 14 proven or probable IFD events (20%) [54]. Although 
pediatric data are lacking, few studies in adult lung transplant recipients, especially 
for cystic fibrosis patients, have indicated that pre-transplant Aspergillus spp. lung 
colonization could be implicated with the presence of post-transpant bronchiolitis 
obliterans accociated with Aspergillus spp. pulmonary infection [55, 56]. 
Contemporary data among 548 pediatric SOT recipients between 2000 and 
2013 from a single center in the US revealed a low overall IFD incidence of 2.2% 
(13/584), or 14.3 IFD events per 100,000 patient-days and a decreasing trend over 
time (accepted article, pending revision, Fisher B). Differences in IFD rates were 
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reported among organ transplant type and over two time periods. In particular, higher 
IFD rates were observed for heart/lung recipients (12.5%), lung only(11.4%) and liver 
(4.7%), compared to kidney and heart (0%).  In addition, over the two time periods 
selected (2000–2006) and (2007–2013), an IFD rate decrease was noted, with a stable 
number of patients in each period, from 4% (25.5 events per 100,000 patient-days) to 
1% (3.9 events per 100,000 patient-days). The number of patients receiving antifungal 
prophylaxis increased over time from 6% for the first time period to 9% for the 
second period, which may explain some but likely not all of the decrease in IFD 
between the two time periods (accepted article, pending revision, Fisher B).  
Outcomes. The mortality associated with IFDs varies by type of SOT, type of 
IFD and time period.  In 1999, Gladdy et al. reported a 33.3% case fatality rate in 
pediatric liver transplant recipients with invasive Candida infections [50]. On the 
contrary, in a recently published study, only one of the 10 patients with IC died 
(mixed infection with C. parapsilosis and IA) [51]. In pediatric heart transplant 
recipients with IFD, the case fatality rate reached almost 50% [52]. More 
specifically,13/22 patients (59%) with IMD and 43/92 (47%) with yeast infections 
died [52]. The case fatality rate from the aforementioned cohort of 548 pediatric SOT 
recipients was 21.4% (3 of 14 pts), including 2 lung recipients and 1 heart/lung 
recipient (accepted article, pending revision, Fisher B).  
 
Invasive fungal disease in primary immunodeficiencies (PID) pediatric patients 
Epidemiology. Among all PID, the epidemiology of IFD has been most 
clearly defined for chronic granulomatous disease (CGD), an inborn error of the 
phagocyte NADPH oxidase complex. While children with CGD are at risk for a wide 
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range of yeast and mold pathogens, Aspergillus spp. and Candida spp. are most 
common [5, 57-64]. Among 155 CGD patients in a French study from 1976-2008, 
42.6% (66/155) developed at least one IFD [58]. In particular, IMDs represented 
61.3% (49/80) of all IFD events. Aspergillus spp. accounted for 65.3%  of these IMDs 
(32/49), with A. fumigatus (28.5%) and A. nidulans (22.4%) being the most common 
Aspergillus spp. [58]. Notably, itraconazole prophylaxis had a significant impact on 
IFD incidence [58].   
Another congenital immunodeficiency associated with an increased 
susceptibility to IFD is Hyper-IgE syndrome (HIES) (i.e. Job’s syndrome) [5,65]. 
Invasive pulmonary aspergillosis occurs in almost 20% of these patients almost 
exclusively secondary to presence of pneumatocysts and bronchectasis due to 
recurrent bacterial infections and due to impaired local STAT3-dependent lung 
epithelial immunity [65,66].  While rare, dissemination to the CNS in these patients 
has been occasionally reported [65, 67]. A recent literature review reported 16 HIES 
cases with rare endemic/dimorphic fungi such as Coccidioides, Cryptococcus and 
Histoplasma, underscoring the vulnerability of this patient group to a wide range of 
fungal pathogens [66].  
The caspase recruitment domain-containing protein 9 (CARD9) represents an 
essential molecule for the production of T-helper cells producing interleukin-17 
pathway. CARD9 deficiency is a PID with impaired Candida spp. killing [67-69]. 
Although large enough cohorts are not available to define the true incidence and case 
fatality rates of IFD in these patients, a case series report suggests that the GI tract and 
in particular CNS are common anatomical locations for Candida infection [69]. Other 
important anatomic locations are the bone and eye [70]. A subsequent case series 
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found that CARD9 deficient patients can also suffer from isolated IA in the CNS and 
GI-tract [71]. 
Outcomes. The overall IFD case fatality rate for CGD reached 17% in one 
study, with a reported reduction of mortality over time from 43% (1985–1990) to 6% 
(1991-2009) [62]. The decrease in mortality for CGD patients over the last 15 years 
has been attributed to high clinical awareness but also to the implementation of 
itraconazole prophylaxis [58,62,64]. Nevertheless, IA remains a major cause of death 
for CGD patients [64]. In HIES, a 17% IFD case fatality rate has been reported [65].  
 
Invasive fungal disease in PICU patients 
Children in PICUs represent a heterogeneous pediatric population with a well-
documented increased risk for developing IFD due to a unique combination of critical 
and complex clinical conditions, including prolonged need of hospitalization, frequent 
invasive interventions, and the presence of foreign devices, such as catheters and 
endotracheal tubes [72].  The predominant cause of IFD in the PICU is IC, while IA is 
mainly observed in children with underlying hematological malignancies admitted to 
the PICU.  
Epidemiology. The incidence of IC and the Candida spp. distribution vary 
among different PICUs and among different time periods. These differences may 
reflect specific institution peculiarities associated with differences in critical care 
practices, differences in geographical niches of Candida spp., and the expansion of 
antifungal prophylactic regimens. For example, from 2005-2009 the incidence of IC 
among seven PICUs in Greece ranged from 0-14.1 cases/1000 admissions with a 
median incidence of 6.4 cases/1000 admissions [73]. Comparable incidences have 
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been reported from Spain with 6.9 cases/1000 admissions during a two-year period 
(1996-1998) [74]. Slightly lower incidences were found in a study from the US with 
3.5 cases/1000 admissions reported during 1997–2004 [75], similar to the results from 
Egypt (3 cases/1000 inpatient-days) [76]. Over a 10-year-period, the incidence of IC 
in PICU patients in a single center study in Germany was 0.59/1000 hospital 
discharges (95% CI, 0.02–1.09) [45]. A more recent update from Spain for the period 
2008-2009 reported an incidence of 4.22 cases/100 PICU admissions [77].  
Richards et al. reported that almost 10% of bloodstream infections in US 
PICUs were attributed to Candida spp. [78], while a study in Israel reported that 
14.4% of bloodstream infections in PICUs were candidemia [79].  C. albicans 
remains the leading cause of IC in the PICU, with an increasing trend of non-albicans 
Candida spp. worldwide. In Europe, C. albicans prevails, with a percentage ranging 
between 37.6 to 55.5% comparable to US studies reporting a 46% of IC caused by C. 
albicans. [73,75-77, 80]. C. parapsilosis is the second leading etiology of IC at 
approximately 20%. The high percentage of C. parapsilosis isolated in the PICU 
emphasizes the need of implementing further infection control bundle measures, as its 
origin is mainly exogenous either through horizontal transmission or adherence to 
foreign devices (such as catheters and other devices) [75]. Other Candida spp. 
account for 10-15% of the isolates, most prominently with C. tropicalis, C. glabrata, 
C. krusei and C. lusitaniae. Differences in the distribution of these species among 
different PICUs have been associated with local practices and therefore it is necessary 
to learn a center’s local epidemiology. 
Outcomes. The case fatality rate of IC in the PICU is difficult to estimate due 
to the high clinical complexity and severity of underlying conditions. Zaoutis et al. 
compared the case fatality rates in children with IC and controls in the PICU and 
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found a statistically significant higher rate of death in children with IC (44% vs 14%; 
OR: 4.22; CI: 2.35, 7.60) [75]. The same group observed a prolonged median PICU- 
and hospital- length of stay for children with IC (35 and 46 days, respectively) [75]. 
Hegazi et al. found a similar case fatality rate in PICU patients (42.4%), while the 
case fatality rate from candidemia was estimated to be 16.7%, similar to the 18.2% 
reported by Vogiatzi et al.  [73,76].  
The impact of species-specific mortality among children in the PICU has been 
evaluated, however, results are conflicting. In another study, children with candidemia 
due to non-albicans Candida spp. were twice as likely to die than children with C. 
albicans [80]. On the contrary, other studies found no significant difference between 
different Candida spp. and case fatality rates [72,75]. In one study, the main species 
associated with higher mortality were C. glabrata, C. krusei and C. tropicalis, and this 
was felt to be most likely due to decreased susceptibility and/or resistant to 
fluconazole among C. glabrata and C. krusei [72].  
 
Invasive fungal disease in NICU patients 
A significant increase in the incidence of IC was initially reported during the 
1990s temporally associated with increased survival rates of premature very low 
birth-weight (VLBW) neonates, while in the last 15 years there has been an overall 
decrease in neonatal IC within European countries and the US [16,17,20,21, 81-84]. 
The cause of this decrease is likely multifactorial and has been correlated with 
prophylactic use of fluconazole and with infection control bundle measures 
eliminating catheter-related bloodstream infections [17, 84].  
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Epidemiology. In a large cohort study including 6956 VLBW neonates, C. 
albicans was the third most common pathogen causing late onset sepsis (6%) [85]. 
Results from a multicenter study (19 centers in the US) among extreme low birth-
weight (ELBW) neonates showed a significant variability in the incidence of IC 
among different centers (2-28%) [86]. Aliaga et al. was among the first to report a 
significant decrease of neonatal IC, dropping from 3.6 per 1000 infants in 1997 to 1.4 
per 1000 infants in 2010 in the US [84]. Similar decreases have now been reported in 
a number of smaller European studies [16,19]. In a UK study, a lower median age of 
diagnosis was reported for C. albicans (11 days) and C. glabrata (9 days) compared 
to other species such as C. parapsilosis (18 days), C. tropicalis (20 days) and C. 
lusitaniae (23 days) in infants < 90 days of age [16]. Irrespective of the age of 
diagnosis, C. albicans remains the most frequent Candida spp. associated with 
neonatal IC, followed by C. parapsilosis, and C. tropicalis; C. glabrata and C. krusei 
are less frequently encountered [87-89]. The incidence of C. parapsilosis infections in 
NICU patients is rather stable when comparing the time period before 2000 (33.5%) 
and after 2000 (27%) [90]. 
Outcomes. Despite a decreasing incidence, neonatal IC is associated with a 
high case fatality rate with an overall estimate of about 20% and increasing to 50% in 
extremely low birth weight (ELBW) infants.  Increased mortality and long term 
neurodevelopmental abnormalities have been associated with neonatal IC, and in 
particular with the occurrence of hematogenous Candida meniningoencephalitis 
(HCME) [86,91,92]. Almost 50% of the infants surviving neonatal IC will have long-
term neurodevelopmental deficits [91-95]. Additional poor prognostic factors for 
neonatal IC outcome include the early onset of IC, delayed catheter removal and 
delayed initiation of antifungal therapy [96-98]. A recently published meta-analysis in 
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2016 showed that fluconazole prophylaxis in ELBW infants not only contributed to a 
significant reduction of IC but also to a reduction in case fatality rates [99].   
 
Conclusion 
There is an ongoing global effort to constantly update our knowledge on the 
incidence and distribution of pathogens causing pediatric IFD.  Continuing and 
actually expanding this effort is necessary to better understand the changing incidence 
and outcomes of IFD and to identify emerging at risk populations. Local monitoring 
of the epidemiology is also necessary to understand the burden of IFD at the 
institutional level. These data are of utmost importance to tailor preventive measures, 
to focus resources on the most susceptible hosts and to implement institution-based 
infection control strategies. Although the spectrum of children vulnerable to IFD is 
wide, the majority of cases are inclusive of the patient populations reviewed in detail 
above. Recent studies on the epidemiology of Candida infections suggest a decrease 
in the infection rates in the last decade.  The reason for this decline is not exactly 
known but often attributed to the utilization of antifungal prophylaxis and improved 
infection control practices.  A gradual shift from C. albicans to non-albicans Candida 
has also been recorded, while a stable incidence of IA was observed. Mortality rates 
remain high depending on the fungal pathogen isolated and underlying condition of 
the pediatric patient. Future work is needed to improve diagnostic capabilities to 
better understand the epidemiology of these infections and to allow for earlier 
initiation of appropriate therapeutic interventions that will result in improved survival 
from these devastating infections.   
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Table 1. Incidence of Invasive Candidiasis and Invasive Aspergillosis from 
contemporary multicenter pediatric studies 
Author 
[ref] 
IFD incidence Time 
period 
Cases 
(N) 
Mortality Type of study Comments 
 Invasive Candidiasis (IC)      
Zaoutis et 
al. [12] 
4.3 /10. 000 pediatric admissions 2000 1118 15.8% Multicenter US study 
(KID 2000) & 
 (NIS 2000) 
 
Analysis showed an absolute 10.0% 
increase in mortality attributable IC 
 
Oeser et al. 
[16] 
 15.2/10.000 person-years 
 
2000-
2009 
1473  NR Multicenter EU study 
(England & Wales) 
Decrease in IC incidence after 2007: 
2.09/100. 000 (2007) versus 1.53/100. 
000 (2009) 
Difference in IC incidence among age 
groups:  Highest in <1 year old 
patients (11.0/100.000) and lowest in 
10-14 year old patients: (0.47/100. 
000) 
Blyth et al.  
[26] 
4.6/10.000 admissions 
4.39/100. 000 population 
(neonates) 
 0.92/100 000 population 
(children) 
 
2001-
2004 
1005 10% 
children 
22% 
neonates 
Multicenter study in 
Australia 
 
Fisher et al. 
[17] 
2.46/10. 000 inpatient days 
(2003) 
0.77/10. 000 inpatient days 
(2011) 
2003-
2011 
4456   14% Multicenter US study Decrease in IC incidence:72% for 
pediatric and 91% for neonatal cases 
Mortality varied: 17.3% (2003) 
versus 11.6% (2011) 
 
 
Santolaya 
et al. [23] 
8.1/10.000  pediatric admissions 2008-
2010 
302 28% Multicenter study in 
Latin America 
 
Cleveland 
et al. [19] 
ATL: 13.3/ 100. 000 person-years 
BTM: 26.2 / 100. 000 person-
years 
 
2008-
2011 
1863 29% 
28% 
Multicenter US study 
population-based 
surveillance 
 
Significant decrease of IC for both 
pediatric and <1 year of age groups. 
 
Cleveland  
et al. [18] 
19/ 10.000 person-years 
(children) 
33.8/ 100. 000 person-years 
(neonates) 
* mixed population children and 
adults (children N=121; <1 yr 
N=113) 
 
 
2008-
2013 
3848* 
 
NR Multicenter US study 
population-based 
surveillance 
 
Baltimore: Decrease in IC incidence 
in neonatal but not in pediatric 
patients: Reported increase 17% 
(2.0/100.000 in 2008 to 2.4/100,000 
in 2013);  
Atlanta:  the decline was greatest for 
persons aged <1 year: reported 
decrease 60% ( 41.7/100,000  in 2008  
to 16.6/ 100.000 in 2013) 
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 Invasive Aspergillosis (IA)      
Zaoutis et 
al. [13] 
437/100. 000 (0.4%) hospitalized 
immunocompromised children 
2000 666  18% Multicenter US study Children with IA had a significantly 
higher mortality and longer median 
length of hospital stay (16 days) than 
immunocompromised children 
without IA (3 days) 
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Table 2. Distribution of Candida spp. causing IFD among pediatric patients from 
multicenter studies between 2000-2017 
Author 
[ref] 
Invasive Candidiasis (IC) 
Fungal species distribution 
Time 
period 
Cases 
(N) 
Mortality Type of study 
 Candida albicans  
Ν (%)  
Non-albicans Candida spp. 
N (%)                               
(three most frequently reported) 
    
Oeser  et al  
[16] 
815 (55.3) C parapsilosis 320 (21.7) 
C glabrata 60 (4.1) 
other 153 (10.4) 
2000-
2009 
1473 NR Multicenter EU study 
(England & Wales) 
Blyth et al.  
[26] 
47 (43.9) C parapsilosis 41 (38.3) 
C glabrata 3 (2.8) 
C krusei 2 (1.9) 
C tropicalis 2 (1.9) 
C orthopsilosis 2 (1.9) 
 
 
2001-
2004 
80 
pediatric 
NR Multicenter study in 
Australia 
Blyth et al.  
[26] 
13 (39.4) C parapsilosis 14 (42.4) 
C glabrata 3 (9.1) 
C tropicalis 1 (3.0) 
 
 
 
2001-
2004 
24 
neonatal  
NR Multicenter study in 
Australia 
Steinbach et al. 
[22] 
 87 (44) 
 
 
 
C.  parapsilosis  45 (22) 
C.  glabrata 21 (11) 
C. lusitaniae 8 (4) 
 
 
2007-
2011 
196 
pediatric 
 
19% Multicenter US & EU 
study (IPFN) 
Steinbach et al. 
[22] 
12 (48) 
 
C. parapsilosis 7 (28) 
C. glabrata 1 (4) 
Other 6 (24) 
 
2007-
2011 
25 
neonatal 
8% Multicenter US & EU 
study (IPFN) 
Santolaya et al. 
[23] 
115 (38.1) 
 
C. parapsilosis 80 (26.5) 
C. tropicalis 44 (14.6) 
C. guilliermondii 31 (10.3) 
 
2008-
2010 
302 
pediatric 
28% Multicenter study in 
Latin America 
 
IPFN: International Pediatric Fungal Network 
NR: not reported 
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Table 3. Distribution of Aspergillus spp. causing IFD among pediatric patients from 
multicenter studies between 2000-2017 
Author 
[ref] 
Invasive mold Diseases (IMDs) 
Fungal species distribution 
Time 
period 
Cases 
(N) 
Mortality Type of study 
 Aspergillus spp.  
N (%) 
Non-Aspergillus Molds 
N (%) 
    
Burgos et al. 
[15] 
A. fumigatus 67 (52.8) 
A. flavus 20 (15.7)     
A. terreus 6 (4.7)  
A. niger 6 (4.7) 
NR 2000-
2005 
139 IA A. fumigatus 38 (52)   
A. flavus 11 (15) 
 
Multicenter EU 
study 
Pana et al.    
[29] 
NR Rhizopus spp. (39.7) 
Lichtheimia spp. (17.5)      
Mucor spp. (12.7) 
2005-
2014 
63 MC 33% Multicenter 
study 
(Fungiscope & 
zygomyco.net ) 
Wattier et al. 
[14] 
A. fumigatus 26 (20) 
 
A flavus 7 (5) 
 
A. niger 6 (5) 
 
  
   
Mucormycoses 17 (13) 
 Rhizopus spp 9 (7) 
 Mucor spp 3 (2) 
Other mold 22 (17) 
 Curvularia spp 4 (3) 
 Exserohilum spp 4 (3) 
 Fusarium spp 4 (3) 
 
2007-
2011 
131 IMIS: 
98 IA 
17 MC 
IMIs 39 (30) 
IA 30 (31) 
MC 6 (35) 
 
Multicenter EU 
and US study 
(IPFN) 
 
IA: Invasive Aspergillosis 
IMIs: Invasive Mold infections 
MC: Mucorales infections 
NR: Not reported 
 
Page 36 of 36
https://mc.manuscriptcentral.com/jpids
Manuscripts submitted to Journal of the Pediatric Infectious Diseases Society
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
